William Blair analyst Matt Phipps has reiterated their bullish stance on CNTX stock, giving a Buy rating on April 30.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Matt Phipps has given his Buy rating due to a combination of factors including the promising development timelines of Context Therapeutics’ key programs, CTIM-76 and CT-95, which are on track for significant clinical readouts in 2026. Despite recent stock price declines, largely influenced by macroeconomic pressures and changes in regulatory leadership, Phipps remains optimistic about the company’s potential.
Context Therapeutics is considered undervalued, with its three wholly owned TCEs showing strong potential. The anticipated Phase I results for CTIM-76 and CT-95, targeting specific cancer types, are expected to provide substantial value. Phipps believes that the regulatory risks are minimal, given that recent approvals have been under the jurisdiction of a different regulatory center, and thus maintains a positive outlook on the stock.
According to TipRanks, Phipps is an analyst with an average return of -10.3% and a 35.07% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Incyte, Bristol-Myers Squibb, and Amgen.
In another report released on April 30, Maxim Group also reiterated a Buy rating on the stock with a $5.00 price target.